Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 11:12:940239.
doi: 10.3389/fonc.2022.940239. eCollection 2022.

A systemic review of taxanes and their side effects in metastatic breast cancer

Jiun-I Lai  1   2   3 , Ta-Chung Chao  1   4   5 , Chun-Yu Liu  1   4   5   6 , Chi-Cheng Huang  4   7   8 , Ling-Ming Tseng  4   5   7   9
Affiliations

A systemic review of taxanes and their side effects in metastatic breast cancer

Jiun-I Lai et al. Front Oncol. .

Abstract

Taxanes-containing chemotherapy constitutes an essential backbone for both early and metastatic breast cancer (mBC). However, the two major taxane drugs-paclitaxel and docetaxel-have distinct safety profiles. In this review, we summarize the safety outcome and management following treatment with both taxanes from selected clinical trials. We utilized PubMed to perform literature search before April 2021. Five phase III randomized controlled trials with reports of individual taxane adverse events (AEs) were included in this review. Grade 3/4 AEs were summarized and discussed extensively. The rates of grade 3/4 neutropenia were higher with docetaxel than with paclitaxel. For non-hematologic grade 3/4 AEs, peripheral neuropathy was more frequent with paclitaxel while fluid retention was more frequent with docetaxel. Compared to paclitaxel, docetaxel had a higher rate of grade 3/4 gastrointestinal AEs. Grade 3/4 myalgia were generally comparable between the two taxanes. Except for neutropenia, the incidence rate of grade 3/4 AEs of taxanes was generally manageable. Peripheral neuropathy was more common with paclitaxel while grade 3/4 neutropenia was more common with docetaxel.

Keywords: adverse event; breast cancer; docetaxel; paclitaxel; systemic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Study searching diagram based on the PRISMA guideline.
See this image and copyright information in PMC

References

    1. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, et al. . Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol (2008) 26(1):44–53. doi: 10.1200/jco.2007.11.3787 - DOI - PubMed
    1. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev (2007) 4):Cd004421. doi: 10.1002/14651858.CD004421.pub2 - DOI - PubMed
    1. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev (2016) 17(S3):43–6. doi: 10.7314/apjcp.2016.17.s3.43 - DOI - PubMed
    1. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: A review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf (2007) 6(5):609–21. doi: 10.1517/14740338.6.5.609 - DOI - PubMed
    1. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, et al. . Randomized phase iii study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol (2005) 23(24):5542–51. doi: 10.1200/jco.2005.02.027 - DOI - PubMed

Publication types